TT-00920
- Generic Name
- TT-00920
A Phase 1 Study of TT-00920 in Healthy Subjects
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05355129
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05043792
- Locations
- 🇺🇸
Pharmaron CPC, Inc., Baltimore, Maryland, United States
Phase I, First-In-Human Study of TT-00920 in Healthy Subjects
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04364789
- Locations
- 🇺🇸
Early Phase Clinical Unit Glendale Adventist Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath